- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04799470
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease - UNMC/Medtronic Collaborative Acute Feasibility Pilot
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease (PD) is a neurodegenerative disorder characterized by both motor and non-motor symptoms. Motor symptoms of PD include the clinical triad of tremor, rigidity, and bradykinesia, and typically lead to the initial diagnosis. While there is yet no cure for PD, medical and surgical therapies have been developed that effectively target the motor symptoms of PD. Patients with PD who demonstrate significant motor fluctuations and dyskinesia are considered for subthalamic nucleus (STN) deep brain stimulation (DBS) surgery. Therapeutic DBS leads to a reduction in pathological neuronal synchronization seen in PD. While continuous high-frequency stimulation is effective for ameliorating motor symptoms, the investigators hypothesize that different stimulation patterns which are designed to better target excessive synchrony in a patient-tailored manner, may result in more efficient and effective therapy with fewer side effects. This overarching hypothesis is supported by prior foundational preclinical and clinical research. Medtronic has developed proprietary technology that allows implantable neural stimulators (INS) to deliver both standard clinical electrical stimulation therapy and to record bioelectric data (i.e. local field potentials; LFPs) through DBS leads implanted in the brain. Medtronic's 3rd-generation sensing DBS INS, Percept PC, is FDA-approved for treating PD and can be used to explore unique biomarkers of brain state changes associated with activities of daily living and disease symptomatic states.
This research will use Percept PC INS latent capabilities to deliver research stimulation. Importantly, all stimulation in this research project will be delivered using charge-balanced pulses, in compliance with all FDA safety guidelines including frequency (≤ 250 Hz) and charge density (30 µC/cm2/phase). At the conclusion of the research study, standard clinical stimulation will be re-activated.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dulce Maroni, PhD
- Phone Number: 402-215-3053
- Email: dmaroni@unmc.edu
Study Contact Backup
- Name: Jonathan Nguyen
- Phone Number: 402-836-9407
- Email: jon.nguyen@unmc.edu
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68118
- Recruiting
- Unversity of Nebraska Medical Center
-
Contact:
- Dulce Maroni, PhD
- Phone Number: 402-215-3053
- Email: dmaroni@unmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with idiopathic Parkinson's Disease who were recommended for STN DBS using standard clinical inclusion and exclusion criteria (e.g., presence of coagulopathy, dementia, untreated depression, pre-existing implanted stimulation system, prior intracranial surgery, history of alcohol or drug abuse)
- Patients have been previously implanted with bilateral STN DBS and the Medtronic Percept PC implantable neural stimulator.
- Patients are optimized for clinical stimulation and medication for at least 3 months post-surgery for the implantation of their DBS system.
- Consent to study participation
- Presence of a robust beta peak (detectable using the Percept BrainSense Survey feature; ≥ 0.7 µV/rtHz), intra-operatively (assessed via Lead Confirm technology from Alpha Omega)
- Good response to stimulation (30% improvement on UPDRS III compared to baseline OFF), at least 3 months post-surgery.
Exclusion Criteria:
- Not currently implanted with the Medtronic Percept INS
- Not willing to participate in the study
- Unstable stimulation with need for frequent reprogramming or further adjustment
- Significant stimulation-induced side effects
- Need for unusual programming parameters such as very high (> 200 Hz) or low (< 100) frequencies (due to cycle limitations)
- The patient has an implanted cardiac device
- The patients Medtronic Percept TM PC indicates elective-replacement-indicated (ERI) at the start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD with DBS
Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
|
Stimulation patterns
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of novel DBS stimulation patterns.
Time Frame: Years 1-2
|
To assess if the novel stimulation patterns provide similar side effect profile, when compared to standard clinical stimulation, tolerability will be assessed by:
|
Years 1-2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to novel DBS stimulation patterns.
Time Frame: Years 1-2
|
To assess if the novel stimulation patterns provide similar motor symptom benefit, when compared to standard clinical stimulation, response will be assessed by:
|
Years 1-2
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aviva Abosch, MD, PhD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0865-20-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Novel DBS stimulation patterns
-
The Cleveland ClinicFarmer FoundationCompleted
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); Emory University and other collaboratorsEnrolling by invitationMultiple Sclerosis | Parkinson Disease | Dystonia | Essential TremorUnited States
-
University of MinnesotaRecruitingChronic Pain | Spinal Cord InjuriesUnited States
-
Jaimie M. HendersonHarvard Medical School (HMS and HSDM); The Cleveland Clinic; Weill Medical College... and other collaboratorsCompletedTBI (Traumatic Brain Injury)United States
-
Tsinghua UniversityPeking Union Medical College Hospital; Beijing Tiantan Hospital; Beijing Pins... and other collaboratorsRecruiting
-
Ruijin HospitalActive, not recruitingMajor Depressive Disorder | Deep Brain StimulationChina
-
Prasad Shirvalkar, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS); United States...Active, not recruitingChronic Pain | Spinal Cord Injuries | Phantom Limb Pain | Post Stroke PainUnited States
-
University of ChicagoMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseUnited States
-
Rabin Medical CenterRecruitingObsessive-Compulsive DisorderIsrael
-
Boston Scientific CorporationRecruitingParkinson's DiseaseUnited States, Korea, Republic of, Italy, Poland, Spain, France, Germany, Israel, United Kingdom, Canada, Argentina, Austria, Belgium, Hungary